(Z)-3-(5-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl)-N-phenylacrylamide | 1333152-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (Z)-3-(5-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl)-N-phenylacrylamide
• 英文别名: (Z)-3-[3-(3-chlorophenyl)-1H-1,2,4-triazol-5-yl]-N-phenylprop-2-enamide
• CAS: 1333152-32-1
• 化学式: C₁₇H₁₃ClN₄O
• 分子量: 324.769
• InChiKey: SEYJUEYOXZWIQG-KTKRTIGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氯苯腈 在 sodium hydrosulfide hydrate 、 magnesium(II) chloride hexahydrate 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 肼 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 26.17h， 生成 (Z)-3-(5-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl)-N-phenylacrylamide
  参考文献：
  名称：

  [EN] NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF
  [FR] MODULATEURS DE TRANSPORT NUCLÉAIRE ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2011109799A8

文献信息

• NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
  申请人：Shacham Sharon

  公开号：US20110275607A1

  公开（公告）日：2011-11-10

  The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

  本发明通常涉及核运输调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑类化合物，这些化合物的合成和使用以及它们的制药组合物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况方面的用途，例如治疗癌症和其他肿瘤性疾病、炎症性疾病、异常组织生长和纤维化疾病，包括心肌病、肺纤维化、肝纤维化、肾小球肾炎和其他肾脏疾病，以及治疗病毒感染（急性和慢性）。
• Methods of promoting wound healing using CRM1 inhibitors
  申请人：Karyopharm Therapeutics Inc.

  公开号：US10202366B2

  公开（公告）日：2019-02-12

  The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R1, R2 and n are as defined and described herein, in a method for promoting wound healing in a subject.

  本发明一般涉及核转运调节剂（如 CRM1 抑制剂）的使用，特别是结构式 I 所代表的化合物： 或其药学上可接受的盐，其中环 A、X、R1、R2 和 n 如本文所定义和描述，用于促进受试者伤口愈合的方法。
• METHODS OF PROMOTING WOUND HEALING USING CRM1 INHIBITORS
  申请人：Karyopharm Therapeutics, Inc.

  公开号：EP2968278B1

  公开（公告）日：2018-12-12
• Methods of Promoting Wound Healing Using CRM1 Inhibitors
  申请人：KARYOPHARM THERAPEUTICS INC.

  公开号：US20160304500A1

  公开（公告）日：2016-10-20

  The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R 1 , R 2 and n are as defined and described herein, in a method for promoting wound healing in a subject.
• Nuclear Transport Modulators And Uses Thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US20170137430A1

  公开（公告）日：2017-05-18

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.